A team of medical researchers and engineers at RSP Systems, in Denmark, working with a pair of colleagues from the Institute ...

Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption for its long-term CBGM later this ...

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose ...

GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and ...

Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM ... Biolinq has ...

A new agreement with OneTwo Analytics AB will allow Glucotrack to leverage next-generation artificial intelligence and machine learning-based analytics to evaluate clinical study data from its continu ...

Glucotrack (GCTK) announced an agreement with OneTwo Analytics AB. Through this collaboration, Glucotrack will leverage next-generation ...

Glucotrack will leverage next-generation artificial intelligence and machine learning-based analytics to evaluate clinical study data from its Continuous Blood Glucose Monitor (CBGM), enhancing ...

GlucoTrack Inc. (2,800% Jump in Message Volume) GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long ...

Goode, PhD, President and Chief Executive Officer of Glucotrack. “This ground-breaking study supports our approach to measuring glucose directly from the blood, rather than interstitial fluid ...